InflaRx NV (STU:IF0)
€ 2.022 0 (0%) Market Cap: 141.14 Mil Enterprise Value: 84.15 Mil PE Ratio: 0 PB Ratio: 2.04 GF Score: 38/100

InflaRx NV Conference Call Transcript

Jan 04, 2024 / 01:30PM GMT
Release Date Price: €1.55 (+7.79%)
Operator

Ladies and gentlemen, thank you for standing by. Welcome and thank you for joining Inflarx's conference call to discuss the results announced today from the multiple ascending dose part of the Phase I study with INF904. (Operator Instructions) Please note that today's call is being recorded. (Operator Instructions) I would now like to turn the call over to Dr. Niels Riedemann, CEO and Founder of Inflarx. Niels, please go ahead.

Niels Riedemann Inflarx NV;CEO

Thank you so much, Lori. Welcome everyone to our today's conference call. We're really excited to host this call today. I'll be leading you through this calling at the beginning. And I will share the presentation with Dr. Pamela Chong, our Chief Medical Officer.

Before I introduce the team on the next couple of slides, please take note. We'll be making forward-looking statements. There's an important notice and disclaimer related to that. And we will also be talking about data proprietary other data. So please take note of that disclaimer.

Next slide, please. So as I mentioned

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot